Skip to content
PubMed This is a summary of 11 peer-reviewed journal articles Updated
Dermatology

Treatment Options and Your Care Team

At a Glance

Because IgA pemphigus is rare, treatment is individualized: dapsone is commonly used, often with corticosteroids, while resistant disease may need off-label retinoids or biologic medicines. A G6PD blood test, follow-up lab monitoring, and specialist dermatology care are important for safety.

Important Note: This guide is designed to help you understand your diagnosis and communicate effectively with your medical team. It does not replace an individualized dermatologist’s assessment. Never start, stop, or alter your doses of dapsone or systemic steroids without speaking to your prescriber.

Because IgA pemphigus is exceptionally rare, there are no large-scale clinical trials to dictate a single “best” treatment. Instead, doctors rely on accumulated case reports and expert consensus to guide your care [1]. The goal of treatment is to stop the formation of new pustules, promote healing of existing ones, and eventually taper medications to the lowest effective dose.

First-Line Treatment Options

A common initial approach involves medications that work in different ways to calm your immune system. Dapsone is frequently used, while topical or systemic corticosteroids and other agents are individualized according to disease extent, subtype, and comorbidities.

Dapsone

Dapsone is a common option for IgA pemphigus because it targets neutrophils, the white blood cells that cause the pustules in this disease [2][1].

  • The Benefit: Many patients see an improvement in itching and the formation of new blisters [3].
  • The Safety Check: Before you take your first dose, you must have a blood test for G6PD deficiency. If you lack this enzyme, dapsone can cause your red blood cells to break down (hemolysis) [4]. Note: Even a normal G6PD result does not completely eliminate the risk of hemolysis, methemoglobinemia, or dapsone hypersensitivity.
  • Monitoring: Your prescriber will establish a specific monitoring schedule for baseline and follow-up CBC, reticulocyte assessment, and liver/renal testing.
  • Immediate Warning Signs: Seek urgent medical advice for severe symptoms: blue/gray lips or extreme shortness of breath (methemoglobinemia) [5]; dark urine, yellowing skin, or worsening fatigue (hemolytic anemia); or fever, sore throat, widespread rash, or facial swelling (agranulocytosis or hypersensitivity).

Systemic Corticosteroids

Oral steroids (like prednisone) are frequently used alongside dapsone, especially during an active flare, to quickly reduce inflammation [1]. Because long-term steroid use can have significant side effects (such as bone thinning or high blood sugar), your doctor will aim to “taper” or slowly reduce your dose under medical supervision once your skin is clear [6]. Never stop these abruptly after prolonged use.

Options for Persistent (Refractory) Disease

If your skin does not clear with initial regimens, or if you cannot tolerate the side effects, your specialist may consider “off-label” treatments. Evidence for these is largely based on small case series or isolated reports, and they have important safety risks.

  • Systemic Retinoids: Medications like isotretinoin or alitretinoin have shown benefit in some recalcitrant cases [7][8]. Risks: These are highly teratogenic (requiring strict pregnancy prevention) and require intensive lipid and liver monitoring.
  • Biologics: Adalimumab and rituximab have been used in resistant cases [2][9]. Risks: These carry significant risks of infection, require screening for tuberculosis and hepatitis reactivation, and have specific vaccination and infusion-related considerations.
  • Treating Associated Conditions: Because IgA pemphigus is sometimes linked to other issues like ulcerative colitis or IgA gammopathy, managing the underlying condition can sometimes be part of the care plan [10][11].

Practical Skin Care and Itch Management

While medications treat the disease, you can support your comfort at home (these do not replace disease-directed treatment):

  • Use cool compresses to numb intensely itchy areas.
  • Avoid friction, tight clothing, and extreme heat.
  • Apply gentle, fragrance-free emollients frequently.
  • Discuss safe, clinician-approved antipruritic (anti-itch) treatments with your doctor.

Building Your Care Team

Managing a rare disease requires a team that is both knowledgeable and collaborative. You may need to seek out a “tertiary care” specialist. Look for a dermatologist at a large academic medical center who specializes in immunodermatology or autoimmune blistering diseases.

To make the most of your first specialist appointment, bring the following “artifacts” with you:

  • Pathology Slides: You can request the actual glass slides or “blocks” from the laboratory that performed your biopsy.
  • Full Lab Reports: Bring the printed results for your Direct Immunofluorescence (DIF) and any antibody blood tests (ELISAs).
  • Medication History: A clear list of every cream or pill you have tried, how long you used it, and whether it helped or caused side effects.
  • Photo Log: If your rash changes over time, bring clear photos of your skin during its worst flares.

Common questions in this guide

What is usually used first to treat IgA pemphigus?
Dapsone is commonly used because it targets neutrophils, the white blood cells involved in pustule formation. Topical or oral corticosteroids may be added or used according to the disease extent, subtype, and other health conditions. There is no single treatment that is best for every person with this rare disease.
Why is a G6PD test needed before taking dapsone?
A G6PD blood test helps identify an enzyme deficiency that can make dapsone cause red blood cells to break down. Even with a normal result, dapsone can rarely cause serious blood or medication reactions, so prescribed follow-up testing remains important.
What symptoms could signal a serious reaction to dapsone?
Seek urgent medical advice for blue or gray lips, extreme shortness of breath, dark urine, yellowing skin, worsening fatigue, fever, sore throat, widespread rash, or facial swelling while taking dapsone. These symptoms can indicate problems such as low oxygen, breakdown of red blood cells, or a serious blood or allergic reaction.
How should corticosteroids be reduced after an IgA pemphigus flare?
The dose should be reduced gradually according to a plan from the prescribing clinician once the skin is controlled. Do not stop systemic steroids suddenly after prolonged use, because abrupt withdrawal can be dangerous.
What options are available if dapsone and steroids do not control IgA pemphigus?
Specialists may consider off-label systemic retinoids such as isotretinoin or alitretinoin, or biologic medicines such as adalimumab or rituximab. These options are supported mainly by limited reports and require careful discussion of risks, including pregnancy-related harm, infection, and laboratory monitoring.
Which specialist should I see for rare IgA pemphigus, and what should I bring?
An academic medical center dermatologist with experience in immunodermatology or autoimmune blistering diseases may be helpful. Bring biopsy slides or blocks, direct immunofluorescence and antibody test reports, a complete medication history, and photos showing severe flares.
Could another health condition be connected to IgA pemphigus?
IgA pemphigus can sometimes occur alongside conditions such as ulcerative colitis or IgA gammopathy. Ask your clinician whether your symptoms or medical history warrant evaluation for an associated condition.

Get notified when new evidence is published on IgA pemphigus.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (11)
  1. 1

    IgA pemphigus: A systematic review.

    Kridin K, Patel PM, Jones VA, et al.

    Journal of the American Academy of Dermatology 2020; (82(6)):1386-1392 doi:10.1016/j.jaad.2019.11.059.

    PMID: 31812619
  2. 2

    A case of IgA pemphigus, with a poor response to dapsone, successfully treated with adalimumab.

    Al-Zahawi S, Kamyab K, Balighi K

    Clinical case reports 2024; (12(5)):e8807 doi:10.1002/ccr3.8807.

    PMID: 38751960
  3. 3

    Imatinib-induced IgA Pemphigus: Subcorneal Pustular Dermatosis Type.

    Sood A, Sinha P, Raman DK, Sinha A

    Indian dermatology online journal 2018; (9(5)):331-333 doi:10.4103/idoj.IDOJ_331_17.

    PMID: 30258803
  4. 4

    Interruption of Sneddon-Wilkinson Subcorneal Pustulation with Infliximab.

    Kretschmer L, Maul JT, Hofer T, Navarini AA

    Case reports in dermatology 2017; (9(1)):140-144 doi:10.1159/000468917.

    PMID: 28559813
  5. 5

    A Case of Dapsone-induced Mild Methemoglobinemia with Dyspnea and Cyanosis.

    Hayama Y, Imanishi H, Yoshimoto N, et al.

    Acta dermatovenerologica Croatica : ADC 2020; (28(4)):249-250.

    PMID: 33835002
  6. 6

    Comprehensive review on the pathophysiology, clinical variants and management of pemphigus (Review).

    Costan VV, Popa C, Hâncu MF, et al.

    Experimental and therapeutic medicine 2021; (22(5)):1335 doi:10.3892/etm.2021.10770.

    PMID: 34630689
  7. 7

    Systemic retinoids for treatment of recalcitrant IgA pemphigus.

    Schauer F, Kern JS, Kiritsi D

    Orphanet journal of rare diseases 2018; (13(1)):163 doi:10.1186/s13023-018-0899-y.

    PMID: 30227880
  8. 8

    IgA pemphigus showing IgA antibodies to desmoglein 1 and 3.

    Hegazy S, Bouchouicha S, Khaled A, et al.

    Dermatology practical & conceptual 2016; (6(4)):31-33 doi:10.5826/dpc.0604a07.

    PMID: 27867744
  9. 9

    A 14-year multicentric follow-up study of atypical pemphigus variants in Italy: the VARIANT_P study.

    Quintarelli L, Bonanni I, Mariotti EB, et al.

    Clinical and experimental dermatology 2026; (51(2)):250-262 doi:10.1093/ced/llaf438.

    PMID: 41072932
  10. 10

    Subcorneal pustular dermatosis-type IgA pemphigus associated with multiple myeloma: A case report and literature review.

    Koga H, Tsutsumi M, Teye K, et al.

    The Journal of dermatology 2023; (50(2)):234-238 doi:10.1111/1346-8138.16516.

    PMID: 35838241
  11. 11

    Immunobullous disease and ulcerative colitis: a case series of six patients.

    Sotiriou MC, Foo CW, Scholes CT, Zone JJ

    The British journal of dermatology 2015; (173(3)):792-6 doi:10.1111/bjd.13872.

    PMID: 25913891

This page is for informational purposes only and does not constitute medical advice or replace an individualized dermatologist’s assessment. Do not start, stop, or change dapsone or corticosteroid doses without speaking with your prescriber.